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Transgenic models of disease
Limitations on studying many human diseases and genetic defects are
caused by a lack of suitable animal models containing the speciﬁed genes and
corresponding disease-associated mutations. This problem has been over-
come, in part, by the development of transgenic technology, which makes it
possible to remove genes or insert foreign, defective, or mutated copies of
genes into mice, to create an animal model of disease that can be analyzed in
the laboratory.
Gene-targeted transgenic models
Gene targeting allows for the production of lines of transgenic mice that
possess either one or two copies of the desired transgene in the correct
location in the mouse genome under the correct transcriptional controls [1].
Homologous recombination is used to replace the endogenous murine gene
in embryonic stem (ES) cells with a mutated gene or the equivalent gene from
another species. These stem cells then can be injected into mouse blasto-
cyst embryos, and contribute toward the developing pup. Any pups born
that are derived from both embryo and stem cell line are called chimeric
mice, and are identiﬁed by the presence of two coat colors (one from the
stem cell line, the other from the blastocyst into which the ES cells were
injected). If the stem cells contribute to the germ line of the chimera, this
animal can be bred to produce a transgenic line that differs from the wild
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type only by the inserted mutation. All lines produced by this method will
express the mutated gene under the correct transcriptional controls, allow-
ing for the direct comparison of transgenic lines that encode different
mutations in the same gene. Although the work described in this article
concentrates on the development of a gene-targeted model for human
Gerstmann-Stra¨ussler-Scheinker syndrome (GSS), we have used the tech-
nology to introduce a number of different mutations into the murine prion
protein (PrP) gene to investigate the precise role of PrP in transmissible
spongiform encephalopathy (TSE) disease [2].
TSE diseases of humans
The TSEs of humans can occur as acquired, sporadic, or familial
diseases. Acquired TSEs include kuru, a disease unique to the Fore people
of New Guinea, and, more recently, variant Creutzfeldt-Jakob disease
(vCJD), which is thought to have been spread by the ingestion of BSE-
contaminated meat. Iatrogenic transmission also has occurred via contam-
inated neurosurgic instruments and the administration of contaminated
human growth hormone [3]. The human TSEs that are less well understood,
however, are the sporadic and familial forms of the disease. Most cases of
human TSEs are sporadic, and are not associated with any speciﬁc source of
infectivity or mutation in the PrP gene. Familial forms of TSE disease,
which include fatal familial insomnia (FFI) and GSS, appear to be inherited
in an autosomal-dominant manner and account for approximately 15% of
human TSEs. These diseases are diagnosed by differing clinical presenta-
tions and pathologic proﬁles, and often are associated with speciﬁc
mutations in the host PrP gene.
PrP is known to be central to the TSE diseases, and its abnormal iso-
form (PrPSc) is thought to be the infectious agent [4]. Mutations in PrP
are hypothesized to destabilize the structure of the host PrP protein, and
promote the conversion of the normal a-helical protein (PrPC) to the ab-
normal b-sheet conformation (PrPSc), thus causing a spontaneous TSE dis-
ease in the absence of any acquired infectious agent [5].
P102L GSS
One speciﬁc mutation, which has been shown to be directly linked to the
development of GSS, is a single base mutation in the human PrP gene that
results in the substitution of leucine for proline at amino acid 102 (P102L
GSS). This mutation has been shown to display 100% penetrance [6], and
many geographically distinct families have been identiﬁed that carry this
mutation and show a family history of neurologic disease [7–9].
A mouse model of the P102L mutation has been produced by the
introduction of multiple copies of a transgene containing the equivalent
mutation at amino acid 101 in murine PrP (P101L) [10]. Transgenic mice
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overexpressing 101L PrP were shown to succumb to a spontaneous neu-
rologic disease between 150 to 300 days of age, depending on the transgene
copy number [10–13]. Low copy number transgenic mice expressing approx-
imately wild-type levels of mutant 101L PrP did not show signs of central
nervous system disorder until after 600 days of age [14]. Approximately
40% of these low copy number transgenic mice developed neurologic disease
before 600 days, however, when inoculated with brain material from sick,
high copy number transgenic mice [11,13]. Hence, in this particular transgenic
model, overexpression of the P101L transgene appeared to lead to a spon-
taneous neurologic disease that could be transmitted to 101L transgenic
mice but not to wild-type mice [11,13]. Previous transgenic experiments have
demonstrated that overexpression of the wild-type PrP gene can cause
neurologic disease in mice [15]. We therefore introduced the 101L mutation
into endogenous murine PrP by gene targeting, in order to study the precise
effect of the 101L mutation in the absence of any possible phenotype caused
by overexpression of PrP. By using this method of transgenesis, we aimed to
determine whether the 101L mutation would destabilize PrP and lead to the
development of spontaneous neurologic disease.
Gene targeting the 101L mutation
Introduction of the P101L mutation
The production of P101L transgenic mice using the double-replacement
gene targeting strategy has been described previously [16–18]. The technique
involves the replacement of the endogenous PrP gene in an ES cell line with
a PrP transgene encoding the 101L mutation (Prnpa101L). ES cell clones
carrying the transgene were injected into 3.5-day blastocysts to produce chi-
meric mice, which were bred with 129/Ola mice to produce progeny hetero-
zygous for the Prnpa101L allele. These animals were then inbred to produce
the homozygous Prnpa101L line.
The resultant transgenic mice (101LL) were viable, and shown by
polymerase chain reaction and sequence analysis to contain the DNA poly-
morphism responsible for the proline to leucine substitution. Southern
blot analysis conﬁrmed that no other alterations had been made to the mice
during gene targeting. Northern blot analysis detected similar levels of PrP
mRNA in both 101LL and wild-type (101PP) mice; however, Western
analysis showed that the steady-state protein levels were marginally lower in
101LL mice [16]. The small differences observed in protein expression levels
may have been due to changes in antibody afﬁnity caused by structural dif-
ferences between 101L and 101P PrP or to altered processing of the mu-
tant protein. Current analysis of the gene-targeted 101LL transgenic mice,
however, has indicated that the 101L PrP protein is expressed and pro-
cessed in the same way as is wild-type 101P PrP (RM Barron, unpublished
results, 2003).
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Does the 101L mutation cause TSE disease in mice?
A group of approximately 400 homozygous (101LL) and heterozygous
(101PL) inbred mice were produced and allowed to age; 110 of these mice
were successfully aged beyond 700 days, with the oldest animal reaching 899
days. No clinical signs of TSE disease were observed in any of these animals.
The brains of all mice were analyzed for early TSE pathology; no vacuo-
lation or PrP deposition was detected. In addition, no protease-resistant
PrPSc was detected by Western analysis of brain tissue. Brain homogenates
from 101LL mice over 600 days old were bioassayed by inoculation
into 101LL and 101PP mice. No disease was transmissible from these aged
brains to wild-type or transgenic mice. Homogenates of spleen from aged
101LL mice also have been inoculated into 101LL and 101PP mice, but no
disease was transmitted from any of the spleens (RM Barron, unpublished
results, 2003).
In contrast to the microinjected 101LL transgenic mice [12,13], the gene-
targeted 101LL mice did not develop spontaneous TSE disease in their life
span, and could not transmit neurologic disease to other mice expressing the
transgene. These two conﬂicting observations simply may reﬂect the dif-
ferent expression levels of PrP in each model. Human P102L GSS can take
over 40 years to develop, and the life span of a mouse expressing normal
levels of 101L PrP (600–800 days) may not be sufﬁcient for the speciﬁc
event that triggers the conversion and accumulation of PrP in the brain
to occur. The overexpression of 101L PrP may, therefore, allow this event
to occur more rapidly, and cause disease. Neurologic disease was observed
in some low copy number P101L microinjected transgenic mice over 600
days old [14], however, suggesting that the wild-type expression levels in
the gene-targeted 101LL transgenic mice should have been sufﬁcient to
allow for the development of disease.
The two P101L mouse models, therefore, diﬀered in more ways than
simply construction, because equivalent protein levels appeared to give
diﬀerent phenotypes in each line of mice. We hope to resolve these issues
in the future by performing experiments that will allow the direct com-
parison of the gene-targeted 101LL mice with the mice overexpressing 101L
PrP, and establish exactly what eﬀect the 101L mutation is having in each
line. With respect to the P101L gene-targeted model, however, the lack of
spontaneous disease led us to investigate whether these mice would display
altered susceptibility to TSE disease. If the 101L mutation did, as suggested,
make the PrP protein unstable and prone to forming PrPSc, then these mice
might be more susceptible to TSE infectivity instead.
Transmission of TSE disease to P101L transgenic mice
Several diﬀerent TSE agents were inoculated into the P101L gene-
targeted transgenic mice [16,26] to assess whether the line was indeed more
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susceptible to TSE disease (Table 1). In complete contrast to the predicted
results, the 101LL mice did not show a general increase in susceptibility due
to the supposedly unstable PrP molecule. The observed alterations in
incubation time, compared with wild-type (101PP) mice, were unpredictable
and appeared to be strain dependent.
Transmission of murine scrapie
Inoculation of 101LL mice with the mouse-passaged scrapie strains ME7
and 22A resulted in a prolongation of the incubation times when compared
with wild-type (101PP) mice (Table 1). A similar effect was observed pre-
viously in transgenic mice overexpressing PrP transgenes that contained
two separate mutations in the same region of PrP [19]. The mutations at
amino acids 108 and 111 were introduced to create a nonmurine monoclonal
antibody epitope in PrP, but their presence in the molecule appeared to
result in a nonspeciﬁc increase in incubation times [19]. The effect of the
101L mutation did not appear to be nonspeciﬁc, because the incubation time
of ME7 was doubled (160 days to 338 days) in 101LL mice [16], whereas the
incubation time of 22A was only increased by approximately 34 days [26],
suggesting that these effects are strain speciﬁc. Transmissions to P101L mice
with the 79A and 139A strains of scrapie have been performed also. All
Table 1
Incubation times of transmissible spongiform encephalopathy (TSE) strains in P101L mice
TSE strain Species
Mouse
strain
Incubation time
(days  SEM) TSE disease
ME7 Mouse 101PP 161  2 10/10
101LL 338  8 18/18
22A Mouse 101PP 493  6 18/18
101LL 527  28 9/16
139A Mouse 101PP 147  2 21/21
101LL >200 0/24
79A Mouse 101PP 139  2 22/22
101LL >200 0/23
P102L GSS Human 101PP 456 1/6
101LL 226  3 15/15
vCJD Human 101PP 373  8 24/24
101LL 556  12 8/18
263K (#1) Hamster 101PP 707 1/4
101LL 374  6 4/4
263K (#2) Hamster 101PP >600 0/20
101LL 464 18 14/16
SSBP/1 Sheep 101PP >400 0/18
101LL 346  5 14/16
Data from Manson JC, Jamieson E, Baybutt H, et al. A single amino acid alteration (101L)
introduced into murine PrP dramatically alters incubation time of transmissible spongiform
encephalopathy. EMBO J 1999;18:6855–64; and Barron RM, Thomson V, Jamieson E, et al.
Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time
across three species barriers. EMBO J 2001;20:5070–8.
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wild-type animals succumbed to disease with the expected incubation times
(139 days and 147 days, respectively; see Table 1), but no 101LL mice
showed signs of disease after 200 days (RM Barron, unpublished results,
2003). These results, therefore, do not agree with the prediction that the
101L mutant protein is unstable and more prone to convert to PrPSc. In
contrast, the presence of the 101L mutation extended the incubation times
of mouse-passaged scrapie strains in a strain-speciﬁc manner.
PrP sequence identity and transmission of disease
Transmission of TSE disease is most eﬃcient when the donor and
recipient of infectivity are of the same PrP genotype [20]. Transmission
occurs rapidly, with tight, predictable incubation times that can be
reproduced on subsequent subpassage in the same species. When attempting
to transmit disease between different species, incubation times usually
are prolonged and occur over a wide range. Often, these incubation times
exceed the life span of the animal, and no clinical signs of disease are
detected. This phenomenon is known as the species barrier, and is thought
to be due to differences in PrP sequence between species. In vitro ex-
periments have shown that the efﬁciency of conversion of PrPC to PrPSc is
greatest when both proteins share identical PrP sequence [21,22]. The
presence of heterologous PrP from another species appears to block this
conversion reaction, causing extended incubation times [21]. Because the
sequences of 101LL and 101PP PrP are identical with the exception of
amino acid 101, these data led us to speculate that sequence identity speciﬁ-
cally at amino acid 101 was more important than was overall sequence
identity when transmitting TSE disease. To further investigate this hypo-
thesis, we performed a series of cross-species transmissions, one of which
contained the corresponding mutation at amino acid 102.
Cross-species transmissions
101LL mice were inoculated with infectivity derived from human (P102L
GSS and vCJD), hamster (263K), and sheep (SSBP/1) sources (See Table 1).
All of these agents, with the exception of vCJD, previously have proved
difﬁcult to transmit to wild-type (101PP) mice. A small number of clinical
cases are usually detected in wild-type mice after a period of over 600 days,
in keeping with the presence of a species barrier. If sequence identity at
amino acid 101 in mouse, and the equivalent amino acid 105 in sheep, and
amino acid 102 in human and hamster PrP is important in TSE disease
transmission, we predicted that incubation times in 101LL mice would
be shortened with P102L GSS, which contains the leucine mutation, but
unchanged with the other sources of infectivity that all contain proline at
this critical position.
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Contrary to our predictions, decreased incubation times were observed
in all cross-species transmissions, with the exception of vCJD (see Table 1).
Transmission of P102L GSS could have been attributed to the presence of
the 102L mutation in the inoculum; however, 263K and SSBP/1 both were
shown to transmit efﬁciently to 101LL mice despite the overall sequence
incompatibility and the nonidentity at amino acid 101. Transmission char-
acteristics with vCJD were reversed. Wild-type mice showed 100% inci-
dence of disease with vCJD at approximately 370 days (see Table 1),
whereas 101LL mice showed increased incubation times of 556 days and
only 45% incidence of disease. These results were totally unexpected, and
showed that identity at amino acid 101 was not critical for the transmission
of disease, but that substitutions at that position could have a major in-
ﬂuence on incubation time of disease. This phenomenon also appeared to
be strain speciﬁc rather than species speciﬁc, because two human sources of
infectivity (GSS and vCJD) showed the ability to decrease and increase
incubation times, respectively, despite the fact that both strains of agent
were propagated in the same species.
Alteration of disease pathology in 101LL mice
The altered incubation times observed on transmission of several
diﬀerent TSE strains to 101LL mice could reﬂect variations in the eﬃciency
of conversion of PrPC to PrPSc due to the presence of a slightly different
conformer of PrPC in the host. This single point mutation in host PrP also
was shown to be capable of altering the disease pathology [26], suggesting
that host PrP plays a major role in the disease process.
Inoculation with vCJD is known to produce disease in wild-type mice
[23], which allowed the comparison of disease pathology between 101PP and
101LL mice that could not have been obtained with P102L GSS and 263K.
Differences were observed in the lesion proﬁle (Fig. 1, Fig. 2B, 2D) and the
distribution of PrP deposition, especially in the hippocampal region (Fig.
2A, C). PrP deposition was evident throughout the entire hippocampus of
the 101LL mice, in contrast to the CA2 targeting seen in 101PP mice (Fig.
2A, C), suggesting that targeting is not deﬁned solely by the strain of agent.
A major characteristic of the strain of agent responsible for vCJD and BSE
is the speciﬁc pattern of vacuolation in mice that is retained after experi-
mental passage through a variety of intermediate species [23–25]. The ability
of the 101L mutation to alter the pattern of vacuolation and incubation
time of vCJD demonstrates the potential for different PrP alleles to de-
termine different phenotypes and incubation times of vCJD in the human
population.
Is PrPSc associated with infectivity?
The prion hypothesis predicts that PrPSc is the agent responsible for
transmission of TSE disease, and levels of PrP accumulation correlate with
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Fig. 1. The extent of the vacuolar change in the brain was assessed in nine areas of gray matter
on a scale of 0 to 5 in each speciﬁc area, and mean scores (calculated from a minimum of six
animals) are shown graphically (error bars  SEM). Gray matter scoring areas: 1, dorsal
medulla; 2, cerebellar cortex; 3, superior colliculus; 4, hypothalamus; 5, medial thalamus; 6,
hippocampus; 7, septum; 8, cerebral cortex; 9, forebrain cerebral cortex. (A) 101PP mice
infected with vCJD. (B) 101LL mice infected with vCJD. (C) RIII mice infected with vCJD.
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levels of infectivity. The amount of PrP deposited in the brains of 101LL
mice was found to vary greatly, however, depending on the strain of agent
inoculated [16,26]. Primary transmissions of both P102L GSS and 263K
hamster scrapie to 101LL mice resulted in clinically and pathologically con-
ﬁrmed TSE disease, but little or no PrP deposition could be detected by
immunocytochemical analysis [16,26]. A very small amount of proteinase K–
resistant material was detected by Western analysis of these tissues, but this
was only after long overexposure of the chemiluminescent blots to x-ray ﬁlm
[16,26]. Therefore, contrary to the theory that 101L PrP would be less stable
and more prone to forming PrPSc, its presence in diseased tissue was difﬁcult
to conﬁrm. The 101L PrP protein was not incapable of forming PrPSc,
however, because 101L PrPSc was detected by Western analysis on primary
transmission of vCJD [26] and ME7 [16], although the degree of deposition
with vCJD was variable and did not correlate with incubation time.
If PrPSc alone is the infectious agent, then it can be predicted that these
models, which contain extremely low levels of PrPSc, also will contain very
low levels of infectivity. Contrary to this prediction, however, both
Fig. 2. Diﬀerences in disease pathology were observed in 101LL and 101PP mice infected with
vCJD. A more widespread pattern of PrP deposition was seen in the 101LL hippocampus (A)
than in the 101PP hippocampus (C). Reduced levels of vacuolation also were observed in the
hypothalamus of 101LL mice (B) when compared with 101PP mice (D). Sections (A) and (C)
were probed with MAb 6H4 and counterstained with haematoxylin, original magniﬁcation  4.
Sections (B) and (D) were haematoxylin-eosin stained, original magniﬁcation  10. Bar is 100
lm in (A) and (C), 40 lm in (B) and (D). (See also Color Plate 14).
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101LL/GSS and 101LL/263K were shown to transmit not only to 101LL
mice, but also to wild-type (101PP) mice, with shortened incubation times
(Table 2). Preliminary analysis indicated that the 101LL/GSS-infected tissue
contained reasonable titres of infectivity associated with very low levels of
PrPSc, and thus raised the question of whether PrPSc is always an accurate
diagnostic marker for the presence of TSE disease. It also gives cause to re-
consider whether PrPSc is the infectious agent, or a pathologic by-product
of the disease process.
What is the role of PrP in TSE disease?
The 101L mutation lies in a region of the molecule shown by nuclear
magnetic resonance spectroscopy to be an unstructured ‘‘ﬂexible tail,’’
which was previously thought to have little involvement in the disease
process. The area of PrP predicted to be involved in species speciﬁcity lies in
the structured C-terminal region of the protein, speciﬁcally involving a-helix
2, and a nearby loop of residues that show some structural diﬀerences
between species [27–29]. The presence of the 101L mutation has been shown
to allow transmission of strains from sheep, hamster, and human sources to
mice without altering any of this critical area in the C-terminus. This indi-
cates that structural compatibility and cofactor binding in the C-terminus
is not the only key to transmissibility of TSE disease. Interactions in the un-
structured N-terminal region appear to be as important.
Recent evidence has suggested that under physiologic conditions, the N-
terminal region of PrP may contain some degree of secondary structure
[30,31], and it is possible that the 101L mutation alters this structure to more
closely resemble the corresponding region in PrPSc of P102L GSS, 263K,
and SSBP/1. This structural identity may be more important in the
transmission of TSE disease than is the overall sequence identity, and may
Table 2
Incubation times on second passage of 101LL transmissible spongiform encephalopathy (TSE)
strains
Strain Species
Mouse
strain
Incubation period
(days  SEM) TSE disease
101LL/263K 101LL mouse 101PP 262  3 10/10
101PL 251  15 8/8
101LL 131  3 7/7
101LL/GSS 101LL mouse 101PP 226  3 16/16
101PL 201  3 20/20
101LL 148  2 18/18
Data from Manson JC, Jamieson E, Baybutt H, et al. A single amino acid alteration (101L)
introduced into murine PrP dramatically alters incubation time of transmissible spongiform
encephalopathy. EMBO J 1999;18:6855–64; and Barron RM, Thomson V, Jamieson E, et al.
Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time
across three species barriers. EMBO J 2001;20:5070–8.
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allow for the direct interaction of the N-terminus with the infectious agent.
Alternatively, the N-terminal region of host PrP may interact directly with
the C-terminal region of PrP that is thought to be involved in species
speciﬁcity, and contribute toward the stability of this critical structure. Mu-
tations in the N-terminal region then would have the potential of alter-
ing incubation times by affecting the critical structure and thus affecting the
efﬁciency of conversion of PrPC to PrPSc. The key to transmission of
TSE disease may therefore lie in the interaction of the ‘‘ﬂexible’’ N-terminal
region of host PrP with the C-terminal region of the same, or other, PrP
molecules.
Summary
Transgenic mice that contain a proline to leucine mutation at amino acid
101 in the endogenous murine PrP gene have been produced by gene
targeting. This line of mice was generated to model the mutation thought to
be responsible for P102L GSS, a familial TSE disease in humans. Gene-
targeted 101LL mice showed no evidence of spontaneous TSE disease in
their lifetime and were unable to transmit any neurologic disease to other
101LL transgenic mice. 101LL mice have, however, been shown to
demonstrate altered susceptibility to several TSE strains, and have shown
reduced incubation times with TSE agents that do not readily transmit to
wild-type mice. The 101L mutation does not appear to destabilize PrP and
promote conversion to PrPSc, because incubation times are increased with
mouse-passaged TSE strains and vCJD. PrPSc also can be difﬁcult to detect
in 101LL mice infected with some TSE strains. We, therefore, have been
unable to substantiate the existence of either genetic disease or infectious
PrP with the P101L transgenic model, but have provided evidence of altered
incubation times of TSE disease in mice carrying the 101L mutation in their
PrP protein. We also have shown that mutations in the N-terminal region of
PrP can have a major inﬂuence over both incubation time and targeting of
TSE disease.
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